Results 151 to 160 of about 56,599 (248)

Focus on biosimilar etanercept – bioequivalence and interchangeability

, 2018
Fabrizio Cantini,1 Maurizio Benucci2 1Department of Rheumatology, Hospital of Prato, Prato, Italy; 2Rheumatology Unit, Hospital S. Giovanni di Dio, Florence, Italy Background: The recent approval of reference etanercept (re-ETN) biosimilars SB4, GP2015 ...
Cantini F, Benucci M
core  

Etanercept Combined with Glucocorticoid and Gamma Globulin for Treating Children with Toxic Epidermal Necrolysis: A Case Report

Yanhua Fu,1 Yuanyuan Xiao,2 Tianji Gao,1 Junxiu Zhang,3 Tianjiao Wang1 1Department of Rheumatology, Baoding Hospital of Beijing Children’s Hospital, Baoding, 071000, People’s Republic of China; 2Department of Dermatology, National Center for Children’s ...
Zhang J, Xiao Y, Wang T, Fu Y, Gao T
core  

Syncope as the Initial Presentation of Takayasu Arteritis in a 57‐Year‐Old Female: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Takayasu arteritis (TA) is a rare chronic granulomatous large‐vessel vasculitis predominantly affecting the aorta and its major branches, leading to stenosis, occlusion, or aneurysm formation. It typically presents in young women, though atypical cases can occur in older adults.
Chao Liu, Jiale Gan, Lili Feng, Yang Yang, Lianwei Dong, Jiabao Liu, Dingguo Zhang   +6 more
wiley   +1 more source

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1476-1484, June 2026.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono, Martin K. H. Ho, Joanna Yang, Tonya Campbell, William Wynne, Dana Shearer, Lene Andersen, Eric Majer, Shaleesa Ledlie, Mina Tadrous, Tara Gomes   +10 more
wiley   +1 more source

Effect of Systemic Immunomodulators on Incidence of Alopecia Areata: A Retrospective Cohort Study

JEADV Clinical Practice, Volume 5, Issue 2, Page 593-596, June 2026.
ABSTRACT Background Alopecia areata (AA) is a chronic autoimmune hair loss disorder. Patients with primary autoimmune diseases commonly use systemic immunomodulators to manage disease and have an increased risk of developing AA. Systemic immunomodulators have diverse immunologic effects, but their impact on AA risk is not well understood. Objectives We
Angela Rose Liu, Nada Hentati, Bethany R. Rohr   +2 more
wiley   +1 more source

Serum and Fecal Calprotectin Levels Do Not Alter Significantly in Patients With Psoriasis Switching to Brodalumab After Loss of Effect From TNF‐α Inhibitors

JEADV Clinical Practice, Volume 5, Issue 2, Page 615-619, June 2026.
ABSTRACT Background Psoriasis is a chronic inflammatory skin disease often associated with systemic conditions like psoriatic arthritis and inflammatory bowel disease (IBD). Calprotectin, an inflammatory biomarker commonly used in IBD, has also been found elevated in psoriasis.
Admir Vižlin, Hans‐Peter Claesson, Ylva Andersch Björkman, Martin Gillstedt, Eva Klingberg, Emanuela Micu, Amra Osmančević   +6 more
wiley   +1 more source

Exploring and Targeting the Connection of Iron and Copper Homeostasis to Neurodegenerative Diseases

MedComm, Volume 7, Issue 6, June 2026.
Iron and copper dyshomeostasis, along with their interactions with key intrinsically disordered proteins (e.g., Aβ, tau, α‐synuclein) have a strong implication in the onset and progression of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Prion diseases (PrDs), Huntington's disease (HD), Wilson's disease (WD),
Xin Liu, Lin Jia, Kerong Wu, Mo Chen, Jichao Sun, Chuanbin Yang, Chengchao Xu, Jie Sun, Jigang Wang, Lingyun Dai   +9 more
wiley   +1 more source

Prescription Pattern and Safety of Biologics in Autoimmune Rheumatologic Diseases in Tertiary Care Hospital of Bihar. [PDF]

Clin Med Insights Arthritis Musculoskelet Disord
Shakur AA, Kumar R, Ranjan RK, Hameed S, Mohan L.   +4 more
europepmc   +1 more source

The Effect of an Autoimmune Protocol (AIP) Diet in Adults With Rheumatoid Arthritis: A Single Arm Crossover Pilot Feasibility Study

Musculoskeletal Care, Volume 24, Issue 2, June 2026.
ABSTRACT Background Individuals with rheumatoid arthritis (RA) often ask whether dietary changes or food exclusions can reduce symptoms. The Autoimmune Protocol (AIP) diet, an elimination‐based approach, is popular on social media, with anecdotal reports of benefit, but lacks clinical evaluation in RA.
Julianne J. McNeill, Gael J. Mearns, Rebecca Grainger, Caryn Zinn   +3 more
wiley   +1 more source

The Longer‐Term Impact of Biosimilar Switching Policies in Patients With Inflammatory Bowel Disease in British Columbia, Canada: A Retrospective, Population‐Based Study

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Background and Aims In 2019, British Columbia (BC) became the first jurisdiction in North America to introduce a mandatory non‐medical switching (NMS) policy requiring patients with Crohn's disease (CD) and ulcerative colitis (UC) to be switched from originator biologics to biosimilar equivalents.
Mark Harrison, Sandra Blitz, Michael Law, Mina Tadrous, Tara Gomes, Fiona Clement, Greg Rosenfeld, Aslam Anis, Nick Bansback   +8 more
wiley   +1 more source